Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity
Open Access
- 1 December 1999
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (12) , 1525-1527
- https://doi.org/10.1023/a:1008350208019
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor ClearanceJournal of Clinical Oncology, 1999
- New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, 1998
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.Journal of Clinical Oncology, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Opportunistic pulmonary infections with fludarabine in previously treated patients with low‐grade lymphoid malignancies: A role for pneumocystis carinii pneumonia prophylaxisAmerican Journal of Hematology, 1995
- Waldenstrom's macroglobulinemiaBlood, 1994
- Fludarabine therapy in Waldenström's macroglobulinemiaThe American Journal of Medicine, 1993
- Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?Acta Medica Scandinavica, 1944